Survivin: An inhibitor of apoptosis in pediatric cancer

Jason R. Fangusaro, Hugo Caldas, Yuying Jiang, Rachel A. Altura*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Survivin is an inhibitor of apoptosis protein (IAP) expressed in a large number of adult malignancies. Its expression levels correlate with more aggressive disease and poor clinical outcome in many of these tumors. As its expression is restricted in normal adult differentiated tissues, it has become of great interest as both a tumor prognostic marker and as a potential biologic target for future anticancer therapies. Survivin expression and Survivin-based therapies have been examined in many of the more common pediatric malignancies. We present an overview of Survivin function and current research exploring its biologic and therapeutic roles in pediatric tumors.

Original languageEnglish (US)
Pages (from-to)4-13
Number of pages10
JournalPediatric Blood and Cancer
Issue number1
StatePublished - Jul 2006


  • Apoptosis
  • Cancer
  • Children
  • Survivin
  • Therapy
  • Tumor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Survivin: An inhibitor of apoptosis in pediatric cancer'. Together they form a unique fingerprint.

Cite this